Asthma and COPD Drugs Market Research Report Information By Disease (COPD, Asthma), Product (Long-Term Asthma Control Medications (Combination Drugs), Inhaled Corticosteroids (Pulmicort, Flovent), Long-acting Beta Agonists), Quick-Relief Medications, (Short-acting Beta Agonists, By Route of Administration (Inhaled, Oral (Intravenous, Subcutaneous)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), and By Region (North America, Europe, Asia-Pacific, and Rest of the World)- Forecast till 2032

Global Asthma and COPD Drugs Market Overview

Asthma and COPD Drugs Market size was valued at USD 37.31 billion in 2023. The asthma and COPD drugs market industry is projected to grow from USD 40.25 Billion in 2024 to USD 73.98 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.9% during the forecast period (2024 - 2032).

The increasing prevalence and incidence rate of asthma and COPD, strong product pipeline, rapidly changing in lifestyle strategies is driving the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Asthma and COPD Market Trends

• Increasing prevalence and incidence rate of asthma and COPD boost the market growth.

The prevalence of asthma and COPD are the major factors contributing to market growth. According to a report published by the Asthma and Allergy Foundation of America in June 2020, 1 in 13 Americans has asthma. Moreover, according to the Global Disease Burden in 2019, around 263 million people suffered from asthma across the globe. It is a reason for major disease burden, including both a decline in quality of life and premature death among the population. Globally, asthma is rated 24th among the leading causes of breathing with disability as well as 34th the leading causes of burden of diseases, as measured by debility adapted life years.

Moreover, as per the Eurostat in 2019, asthma affected around 6% of the European population which is a 3% increase as compared to 2014. In Finland around 9% of people suffered from asthma, followed by France and Germany (both 8%). Thus, increasing the prevalence and incidence rate of asthma and COPD disease positively impacts new therapeutics development as well as raising the demand for asthma and COPD therapeutics across the globe which propel the growth of asthma and COPD drugs market.

Asthma and COPD Drugs Market Segment Insights

Asthma and COPD drugs Disease Insights

The Asthma and COPD Drugs Market segmentation, based on disease, includes COPD and asthma. The COPD segment held the majority share in 2022 in the Asthma and COPD Drugs Market revenue. COPD is a type of lung disease in which the airways get narrower and then swell, hence resulting in the production of extra mucus. According to the World Health Organization, as of November 2019, approximately 235 million people had COPD globally. Furthermore, according to data published by the Asthma and Allergy Foundation of America in February 2018, more than 25 million people in the Americas had COPD.

April 2019: Boehringer Ingelheim has invested USD 111.4 million to expand its production operations at its site in Dortmund and Ingelheim for increasing capacity for next-generation medical device (Respimat, a respiratory medication).

Asthma and COPD Drugs Product Insights

The Asthma and COPD Drugs Market segmentation is based on product that includes long-term asthma control medications, quick-relief medications. Long-term asthma control medications are further sub segmented into combination drugs, anticholinergics, inhaled corticosteroids, long-acting beta agonists, theophylline, and others. The combination drug sub segmented into seretide/advair, symbicort, relvar/Breo ellipta, flutiform, dulera, and others. Anticholinergics is further subsegmental into spiriva, and others. Inhaled corticosteroids are further sub segmented into pulmicort, flovent, qvar, and others.  Quick-relief medications are further sub segmented into Short-acting beta agonists, ipratropium bromide (Atrovent), oral and intravenous corticosteroids, and others. Short-acting beta agonists are further sub segmented into ventolin, proair, and others. The long-term asthma control medications segment has dominated the market in 2022 due to the long-term asthma control medications are an important part of treatment for individuals with persistent asthma. These medicines aid in preventing symptoms but they shouldn’t be used as relieve symptoms.

June 2022: Glenmark launched the novel-fixed dose combination (FDC) drug, Indacaterol plus Mometasone for patients suffering from uncontrollable asthma in India. The company launched this FDC drug under the brand name of Indamet.

Asthma and COPD drugs Routes of Administration Insights

The Asthma and COPD Drugs Market segmentation is based on treatment that includes oral and inhaled. The oral segment has dominated the market in 2022 due to the oral route of administration is adopted in the form of tablets, such as Symbicort, Foradil, and Zafirlukast. Shorter treatment time is expected to drive the market growth. Moreover, this route of administration is the least expensive, convenient, and safe, which increases its popularity, hence driving the market growth. Oral route of administration is preferred mostly in the case of acute asthma. It is also preferably used for the treatment of asthma and COPD in children because it is difficult for them to use inhalers.

Asthma and COPD drugs Distribution Channel Insights

The Asthma and COPD Drugs Market segmentation is based on distribution channel that includes hospital pharmacies, retail pharmacies and Online Pharmacies. The retail pharmacies segment has dominated the market in 2022 due to the increasing number of retail pharmacies in comparison to hospital pharmacies makes it more convenient for patients to buy drugs. In 2016, the number of stores of the top 10 retail pharmacies was about 31,053 in the United States. Furthermore, asthma and COPD patients generally do repeat purchases in retail pharmacies after the doctors have prescribed the drug.

October 2022: Verona reported positive analyses from its phase 3 ENHANCE-2 clinical trial of ensifentrine that treats chronic obstructive pulmonary disease (COPD). Ensifentrine is a product candidate that combines bronchodilator and anti-inflammatory activities in one compound.

Figure 2: ASTHMA AND COPD DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022 & 2032 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Asthma and COPD drugs Regional Insights

By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America accounted for the largest market share in 2022 owing to the North Americas is expected to command the largest market share due to the rising patient population suffering from asthma and COPD in the region. According to the American Academy of Allergy Asthma & Immunology, in 2020, approximately 27 million population suffered from asthma in the US. This approximates 1 in 12 people. More than 22 million US adults ages group 18 and more than 18 years have asthma. Furthermore, rising research and development activity for new therapeutics development, presence of major key players, growing demand of better therapeutic treatment driving the growth of asthma and COPD drugs market in the North America region.

Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: ASTHMA AND COPD DRUGS MARKET, BY REGION, 2022 & 2032 (USD BILLION)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe Asthma and COPD drugs market is expected to account for the second-largest market share due to the growth of the market are the increase in the prevalence of asthma and COPD disease. Increasing healthcare expenditure, growing research, and development activity. In addition, as per the National Health Institute in 2020, the prevalence of asthma is around 8.2% in adults while in UK asthma prevalence 17.6% in the UK. Furthermore, the Germany asthma and COPD drugs market held the largest market share in 2022 and UK asthma and COPD drugs market is the fastest growing market in the Europe region.

The Asia-Pacific Asthma and COPD drugs market is expected to grow at a CAGR of 8.20% from 2019 to 2032. This is due to an increase geriatric population, strategic alliance such as supply agreements, merger & acquisition by major key players. Availability of cheap labor cost, increasing number of companies presence in the region and growing demand of better therapeutics are driving the growth of asthma & COPD drugs market. Moreover, Japan asthma and COPD drugs market held the largest market share in 2022 and India asthma and COPD drugs market is the fastest growing market in the Asia-Pacific region.

The Rest of the World includes the Middle East, Africa, and Latin America. Latin America holds the major market share in the middle east and Africa region due to the region’s growth is attributed to an increasing better medical facility, rising awareness about the better treatment are raise the demand of asthma & COPD drugs market across the region which drives the growth of the market. This is expected to bolster the market of asthma and COPD drugs in this region.

Asthma and COPD drugs Key Market Players & Competitive Insights

The Asthma and COPD Drugs Market is distinguished by the presence of numerous global, regional, and local players catering to the increasing need for products in the emerging threat. Moreover, factors such as the increasing threat of bioterrorism, growing awareness of the potential for pandemics, and advances in biotechnology have made it possible to develop new and more effective asthma and COPD drugs products. Moreover, the numerous pipeline products are responsible for the intense competition and huge opportunities during the forecast period.

Additionally, manufacturers are entering into strategic alliances such as acquisitions, mergers, collaborations, product launches, and product approvals. These strategic alliances are creating intense rivalry for the newcomer as well as for the existing brand.

GlaxoSmithKline PLC is a science-led global healthcare company. The company’s priority is to develop and improve the pipeline of medicine. It has three major business segments, namely, pharmaceutical medicine, vaccines, and consumer healthcare products. In the year 2018, It delivers 2.3 billion packs of medicine, 770 million vaccines, and 3.8 billion consumer healthcare products. The company has a global foothold with 13 manufacturing units across ten countries, but the US market contributes major revenue. The main focus area of the company’s R&D is infectious diseases that affect the children as well as the young population in developing countries.

Key Companies in the Asthma and COPD drugs Market Include

• Teva Pharmaceutical Industries Ltd (Israel)


• GSK plc (UK)


• Hoffmann-La Roche Ltd (Switzerland)


• AstraZeneca (UK)


• Boehringer Ingelheim International GmbH (Germany)


• Sanofi (France)


• Koninklijke Philips N.V. (Netherlands)


• BD (US)


• Merck & Co., Inc (US)


• Sunovion Pharmaceuticals, Inc (US)

Asthma and COPD Drugs Industry Developments

April 2021: Hikma Pharmaceuticals PLC received US FDA approval for its product ADVAIR DISKUS in the US. This US FDA product approval strengthen company business in the US and boos the revenue growth in the US asthma and COPD drugs market.

February 2022: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) offered a positive opinion commending approval for Sanofi’s Dupixent (dupilumab) as an add-on maintenance therapy to treat children of the age of 6 to 11 years with severe asthma with type 2 inflammation.

Asthma and COPD drugs Market Segmentation

Asthma and COPD Drugs Disease Outlook

• COPD


• Asthma

Asthma and COPD Drugs Product Outlook

• Long-term Asthma Control Medications
  
  
  
  • Combination Drugs
    
    
    
    • Seretide/Advair
    
    
    • Symbicort
    
    
    • Relvar/Breo Ellipta
    
    
    • Flutiform
    
    
    • Dulera
    
    
    • Others
    
    
    
    
  
  
  • Anticholinergics
    
    
    
    • Spiriva
    
    
    • Others
    
    
    
    
  
  
  • Inhaled Corticosteroids
    
    
    
    • Pulmicort
    
    
    • Flovent
    
    
    • Qvar
    
    
    • Others
    
    
    
    
  
  
  • Long-acting Beta Agonists
    
    
    
    • Theophylline
    
    
    • Others
    
    
    • Quick-Relief Medications
    
    
    • Short-acting beta agonists
    
    
    • Ventolin
    
    
    • ProAir
    
    
    • Others
    
    
    
    
  
  
  • Ipratropium bromide (Atrovent)
    
    
    
    • Oral and Intravenous Corticosteroids
    
    
    • Others
    
    
    
    
  
  
  
  

Asthma and COPD Drugs Route of Administration Outlook

• Inhaled


• Oral


• Others (Intravenous, Subcutaneous)

Asthma and COPD Drugs Distribution Channel Outlook

• Retail Pharmacies


• Hospital Pharmacies


• Online Pharmacies

Asthma and COPD drugs Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Middle East and Africa
  
  
  
  • Middle East
  
  
  • Africa